In any case, the lack of immune responses exhibited in the early stage of coronavirus infections, may suggest that TLR5 agonists could be most valuable in the early phase of infection, whereas the media hype chloroquine could be most useful against late stage infection, since chloroquine is an inhibitor of nucleic acid recognizing TLR-mediated inflammatory responses [253]. The gene discussed is TLR5; the disease is infection.